EP1860106A1 — Tricyclic thrombin receptor antagonists
Assigned to Merck Sharp and Dohme LLC · Expires 2007-11-28 · 18y expired
What this patent protects
Claimed is a process for the manufacture of compounds of the following general formula (II): wherein R x represent a group selected from COOCH 2 CH 3 , SO 2 CH 3 , CONHCH 3 , and COCH 3 , comprising the step of reacting the compound of the following formula (α-13) w…
USPTO Abstract
Claimed is a process for the manufacture of compounds of the following general formula (II): wherein R x represent a group selected from COOCH 2 CH 3 , SO 2 CH 3 , CONHCH 3 , and COCH 3 , comprising the step of reacting the compound of the following formula (α-13) with a compound of the general formula R x -X, wherein X represents a leaving group and wherein R x is as defined above. Also claimed is a process for the manufacture of pharmaceutical compositions comprising compounds of the following formula (II) or pharmaceutically acceptable salts or solvates thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.